EUVIMEDEUVIMED entdecken
Crossref

Will the Food and Drug Administration’s New Standard of Requiring Only One Trial for a New Drug Application/Biologic License Application Have Repercussions for Medical Communicators?

Thomas Schindler

AMWA Journal · 16.06.2026 · 41 (2)

DOI: 10.55752/amwa.2026.569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AMWA Journal, online erschienen am 16.06.2026. Verfasst von Thomas Schindler.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On February 19, Prasad and Makary published a “Sounding Board” opinion piece in the New England Journal of Medicine (NEJM).1 They announced that the Food and Drug Administration (FDA) will move away from its long standing practice of requiring 2 well-controlled clinical trials for marketing approval. From now on, a single pivotal trial—supported by “additional evidence” (for example, biomarker data, mechanistic evidence, real-world data, or postmarketing surveillance)—will become the new default for many drug approvals.

Zitieren

APA

Schindler, T. (2026). Will the Food and Drug Administration’s New Standard of Requiring Only One Trial for a New Drug Application/Biologic License Application Have Repercussions for Medical Communicators?. AMWA Journal, 41(2). https://doi.org/10.55752/amwa.2026.569

Vancouver

Schindler T. Will the Food and Drug Administration’s New Standard of Requiring Only One Trial for a New Drug Application/Biologic License Application Have Repercussions for Medical Communicators?. AMWA Journal. 2026;41(2). doi:10.55752/amwa.2026.569

BibTeX
@article{Schindler2026,
  author = {Schindler, Thomas},
  title = {Will the Food and Drug Administration’s New Standard of Requiring Only One Trial for a New Drug Application/Biologic License Application Have Repercussions for Medical Communicators?},
  journal = {AMWA Journal},
  year = {2026},
  volume = {41},
  number = {2},
  doi = {10.55752/amwa.2026.569}
}
Kostenlos starten →